PainReform Faces Nasdaq Compliance Challenge Amid Drug Development
Company Announcements

PainReform Faces Nasdaq Compliance Challenge Amid Drug Development

PainReform (PRFX) has released an update.

PainReform, a clinical-stage pharmaceutical company, received a notification from Nasdaq for not meeting the minimum stockholders’ equity requirement. Despite this, the company’s shares will continue to trade on Nasdaq, and they have until December 19, 2024, to submit a compliance plan. PainReform is focused on developing PRF-110, a product aiming to provide extended postoperative pain relief.

For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyPainReform receives noncompliance notification from Nasdaq
TheFlyPainReform cut to Hold at Maxim amid ‘changed’ market dynamics
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App